Mr. Andréasson, Dr. Archinard and Ms. Windels currently serve on our remuneration and appointments committee. Dr. Archinard is the chairperson of our remuneration and appointments committee.
Currently, Sven Andreasson is administrator of Galenos. He is the former Chief Executive Officer of Isconova AB (Uppsala, Sweden), CEO of Beta-Cell NV (Brussels), Active Biotech AB (Lund, Sweden) and several companies in the Pharmacia group. He acquired extensive experience in the international biotechnology companies and in the pharmaceutical industry. Sven Andreasson received a BS degree in science and business administration and in Finance from Stockholm School of Economics and Business Administration.
Philippe Archinaud was appointed General Manager, CEO and director of Transgene on 7 December 2004, after 15 years in the BioMerieux group in different positions including management of the US subsidiary. Philippe Archinaud had served as CEO of Innogenetics N.V. since March 2000. He is a chemical engineer and received a PhD in biochemistry from the University of Lyons, with an advanced degree in the PMD management programme from the Harvard Business School.
Hilde Windels has over 20 years’ experience in corporate finance, capital markets and strategic initiatives. She is the Chief Financial Officer and Managing Director of Biocartis, a molecular diagnostics company based in Belgium. Before Biocartis, Hilde was Devgen’s CFO (Euronext: DEVG) from 1999 until the end of 2008 and was member of Devgen’s board from 2001 until the end of 2008. From early 2009 to mid 2011, she worked as independent CFO for a few private biotechnology companies, and she sat on the board of MDX Health (Euronext: MDXH) from June 2010 until end of August 2011. Previously, she was responsible at ING for commercial banking in one of the Belgian areas. She holds a degree in Economics from the University of Leuven (Belgium).